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Point: Universal Screening for Gestational
Diabetes Mellitus
G
estational diabetes mellitus (GDM)
is one of the most common medical
disorders found in pregnancy.
Rates can range from 2 to 10%, and
sometimes much higher, depending on
the population being tested and the diag-
nostic criteria being used (1). The preva-
lence of GDM ultimately reﬂects the
background rate of type 2 diabetes. There
has also been an increase in the rate of
GDM over the last generation, possibly
related to community lifestyle factors as
well as better case ascertainment (2,3).
Signiﬁcance of GDM
GDM is associated with a trilogy of
risks. Signiﬁcant pregnancy complica-
tions including increased perinatal
morbidity and possibly mortality can
occur (4,5). A diagnosis of GDM also
identiﬁes a mother at high risk for the
future development of type 2 diabetes
(1). The effects of maternal hyperglyce-
mia (of any kind) are associated with
the development of metabolic problems
including type 2 diabetes in the off-
spring (6). It is, perhaps, for this effect
of intrauterine programming that the
disorder is most worthy of detection.
It has now been demonstrated that
the treatment of GDM improves preg-
nancyoutcomes.IntheAustralianCarbo-
hydrate Intolerance Study in Pregnant
Women (ACHOIS), the incidence of seri-
ous perinatal complications (a composite
of death, shoulder dystocia, nerve palsy,
and fracture) was 4% among women ran-
domized to routine care compared with
1% among the intervention group (5).
The number of GDM cases that needed to
betreatedtopreventoneseriousperinatal
complication was 34. This indicates that
excess serious perinatal complications
will occur in 3% of cases of untreated or
unrecognized GDM. This is a most com-
pelling immediate argument for the
screening of GDM given that the failure
to identify a woman with GDM denies
her the opportunity to have treatment
for potentially preventable serious fetal
complications.
Why conduct selective screening for
GDM?
Therefore, if we accept that GDM is a di-
agnosis worthy of consideration, then as
manywomenaspossibleshouldbetested
for this problem. This can only be
achieved through universal screening.
However, it is well-known that women
with GDM have certain deﬁnable risk fac-
tors, and currently both the American Di-
abetes Association (7) and the American
College of Obstetricians and Gynecolo-
gists (8) recommend using such risk fac-
tors to selectively screen for GDM. Is it
possible to use selective screening based
on risk factor identiﬁcation that would
identify the overwhelming majority of
cases, be easy to implement, be cost effec-
tive, and would not lead to any harm?
The main and ongoing concern with
selective screening based on historical
and clinical risk factors is that most stud-
ies have found that if such a system were
used, a signiﬁcant proportion of GDM
cases would be missed. An early study,
which did not include age as a risk factor,
found that risk factor screening would
have missed 53% of GDM cases (9). In
another study, using age 30 years as a
risk factor would have resulted in 22% of
missed cases of GDM (10). Reducing the
age threshold to 25 years decreased the
number of subjects who would be missed
to 7%; however, the number of subjects
whowouldneedtobescreenedincreased
from 58 to 78%. More recent studies ex-
amining broader criteria for risk factor
screening found that only 3–9% of GDM
cases would be missed but 80–90% of
subjects would need to be screened
(11–13).
In the well-designed Toronto Tri-
Hospital Gestational Diabetes Project,
3,131 pregnant women aged 24 years
underwent a 50-g glucose challenge test
(GCT) followed by a 100-g oral glucose
tolerance test (GTT) (14). Subjects were
randomly divided into a derivation group
and a validation group. A clinical scoring
system based on age, BMI, and race was
used to divide subjects into those at low,
intermediate, and high risk of GDM. The
exclusion of low-risk subjects from bio-
chemical screening would allow 35% of
women to avoid the GCT. Applying this
to the validation group, screening algo-
rithms using the clinical score, and vary-
ing the glucose threshold on the GCT to
select patients for the GTT enabled a de-
tection rate of up to 83% and a false-
positive rate (from the GCT) of 13–16%.
Although the results of the Toronto
Tri-Hospital Gestational Diabetes Project
have been used to champion the argu-
ment for selective screening, we believe
that knowingly failing to detect any
woman, let alone a number such as 17%
of women with GDM, can never be sanc-
tioned. As illustrated above, reducing the
thresholdorincreasingthenumberofcri-
teria for selective screening improves the
sensitivity; however, this also decreases
thespeciﬁcity.Ultimately,thisdefeatsthe
main purpose of selective screening,
which is to reduce the number of tests
needed to be performed.
Naylor et al. (14) have also indicated
that the screening strategy of the Toronto
Tri-Hospital Gestational Diabetes Project
detects more cases of GDM among over-
weight older women and misses more
cases among leaner younger women.
Theyhaveassertedthatthisshiftindetec-
tion pattern is unlikely to be harmful, on
thepresumptionthatthemissedcasesub-
jects are at lower risk. However, this has
beenrefutedbyastudythatdemonstrated
that GDM pregnancies among lean young
Caucasian women were similar to other
women with GDM, in terms of insulin
use, emergency cesarean section, and the
proportion of large- and small-for-
gestational-age babies (11). In this study,
exclusion of this low-risk group from
screening would have resulted in nearly
10% of missed cases of GDM; however,
some 80% would have still required
testing.
Thereareadditionaldatademonstrat-
ing that women without risk factors are
no less prone to the complications of
GDM. Weeks et al. (15) have found that
rates of macrosomia, cesarean section,
and shoulder dystocia are similar to those
in women with GDM who have risk fac-
tors. There is also a randomized con-
trolled trial that compared pregnancy
outcomesinwomenwithriskfactorswho
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in women covered by universal screening
with a 50-g GCT (16). The incidence of
GDM diagnosed in the universal screen-
ing group was almost double that in the
risk factor group (2.7 vs. 1.45%, P 
0.03). Macrosomia (large for gestational
age), admission to neonatal intensive
care, preterm delivery, and hyperbiliru-
binemia were also more common in the
risk factor group. We know that selective
screening will miss some cases of GDM in
women who do not have risk factors.
These data indicate that we cannot afford
to do so.
Inpractice,theapplicationofriskfac-
tor screening is challenging. Further-
more,potentialadditionalcomplexityhas
recently been added to the selective
screening paradigm by the ﬁnding that
the other established risk factors are less
relevantforthepredictionofGDMamong
women without a family history of diabe-
tes (17). The investigators have suggested
that a different set of risk factors might
need to be applied for selective screening
in women without a family history of di-
abetes. In an editorial to the Tri-Hospital
study, Greene has stated that “despite its
scientiﬁc merits, busy obstetricians are
unlikely to wend their way through this
complex diagnostic schema” (18).
In support of this view, a survey con-
ducted in New Zealand has shown that
even well-trained midwives have difﬁ-
culty recalling the recognized risk factors
for GDM (19). Seventy-nine percent per-
formed risk factor screening, but only a
median of three risk factors could be
nominated by the respondents, with fam-
ily history (89%), glycosuria (63%), and
obesity (55%) most commonly men-
tioned. Only 26% included age as a risk
factor. Although this may be more easily
overcome in large protocol-driven insti-
tutions, GDM screening is often per-
formed by private obstetricians, general
practitioners, and community midwives.
GDM is but one issue they need to be
aware of; the simpler the process, the less
likely there will be mistakes.
Although our interest is primarily the
well-being of a mother and a child, in to-
day’senvironment,themedical-legalcon-
sequences of a missed diagnosis must
surely be an additional concern. If there
was a suggestion of undiagnosed GDM,
could a serious complication from the
pregnancy, a failure to detect a woman at
risk of type 2 diabetes who has developed
some complications by the time of diag-
nosis, or an adult with type 2 diabetes
concerned that this may have in part de-
veloped because of adverse intrauterine
programming be defended? Surely, the
way to overcome this concern is to test all
women in all pregnancies.
Universal screening with a GCT or
universal testing with a GTT?
If universal testing is preferred, for the
variety of very practical reasons outlined
above, then there is another dimension to
consider. The gold standard for the diag-
nosis of GDM is a GTT—irrespective of
howitisperformedandwithallitsknown
imperfections. In a similar vein to our de-
termination that selective testing for case
identiﬁcation is unsatisfactory, should we
also critically look at the GCT?
The GCT has a signiﬁcant false-
negative rate (20) and is more likely to be
positive in the afternoon (21), and the re-
sults can vary depending on the time
since the last meal (22). Women who
have a positive GCT need to return on a
second occasion, which is inconvenient
andmustinevitablyresultinadelaytothe
initiation of treatment. Does this delay re-
sult in any compromise of the pregnancy
outcomes? To our knowledge, this ques-
tion has not speciﬁcally been addressed;
however, Langer et al. (23) reported on
poorer outcomes for women who are di-
agnosed late and effectively have inade-
quate treatment.
Ithasalsobeenshownthatupto23%
of women who screen positive on a GCT
fail to attend their diagnostic GTT (24).
Even in the Toronto Tri-Hospital Gesta-
tional Diabetes Project, where subjects
were recruited with the explicit under-
standingthattheywouldhaveaGTTafter
a GCT, 10% did not proceed with the
GTT (22). Data on the subject of how
many women fail to attend the diagnostic
GTT or who have it late are inadequate,
but clearly there will be women with pos-
sible GDM who are disadvantaged by this
two-stage procedure.
ThediagnosisofGDMbasedonselec-
tive testing will require a large percentage
of pregnant women to be tested and will
deﬁnitely miss some cases. Further im-
precision is guaranteed by using a two-
stage procedure to arrive at the diagnosis.
However, all of these pitfalls can easily be
avoidedbytheimplementationofuniver-
sal testing with a diagnostic GTT. In
resource-poor areas and/or where there is
a known low rate of GDM, some alterna-
tive to universal testing could be consid-
ered. Otherwise, our responsibilities to
our patients and their offspring demand
that all women should be offered a test
with a single-step deﬁnitive GTT in every
pregnancy.
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